Mar 30th, 2009 - Bloomberg
Related topics:
March 30 (Bloomberg) -- Heart stents made by BostonScientific Corp., the world’s biggest seller of the artery-clearing devices, were less effective in studies than those fromAbbott Laboratories, Johnson & Johnson and Medtronic Inc.
Related stories:
Payback time for Goldman Sachs?
Mar 31st, 2009 - CNNMoney
NEW YORK (Fortune) -- For Goldman Sachs, making money is usually easy. Giving it back, on the other hand, is turning into quite a challenge. Next month, the New York-based...
Candy Spelling's Holmby Hills mansion listed for $150 million
Mar 28th, 2009 - Los Angeles Times
There are homes. And then there is Candy Land -- all 56,500 square feet of it. Candy Spelling, widow of legendary TV producer Aaron Spelling, has put her 4.7-acre residence in Holmby Hills up for sale...
Castor Pollux Will Buy Madoff Unit, Bankruptcy Trustee Says
Mar 27th, 2009 - Bloomberg
March 28 (Bloomberg) -- Castor Pollux Securities LLC willbuy Bernard L. Madoff Investment Securities LLC’s market-makingbusiness for at least $500,000 and perhaps as much as $15.5million...
Mortgage Rates as ‘Good as It’s Going to Get,’ Koskinen Says
Mar 27th, 2009 - Bloomberg
March 27 (Bloomberg) -- Mortgage rates are “probably asgood as it’s going to get” and the housing market is likely torebound sooner than some forecasts, Freddie Mac interim ChiefExecutive Officer John A...
Related videos from YouTube:
1:14
1:49Importance of Antiplatelet Therapy with Drug-Eluting Stents
Sept. 2005 - FDA has received a number of reports of adverse events that occurred in patients who received drug-eluting coronary stents and then stopped taking their antiplatelet medication prematurely. These events included stent thrombosis ...
2:10PROMUS Element Stent
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS® Element™ Everolimus-Eluting Coronary Stent System, the Companys third-generation drug-eluting stent (DES) technology. The PROMUS ...
0:13TAXUS Liberté Paclitaxel-Eluting Stent expanding in a ...
Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the US Food and Drug Administration (FDA) to market its second-generation TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System. The ...
